CORRECTION article

Front. Immunol., 29 February 2024

Sec. Viral Immunology

Volume 15 - 2024 | https://doi.org/10.3389/fimmu.2024.1385729

Corrigendum: ErbB2/HER2 receptor tyrosine kinase regulates human papillomavirus promoter activity

  • 1. Institute for Virology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany

  • 2. University of Bonn, Faculty of Mathematics and Natural Sciences, Life & Medical Sciences (LIMES) Institute, Bonn, Rheinland-Pfalz, Germany

  • 3. Institute for Immunology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Rheinland-Pfalz, Germany

  • 4. Helmholtz Institute for Translational Oncology (HI-TRON) Mainz, Mainz, Rheinland-Pfalz, Germany

In the published article, there was an error in Figure 7 as published. The x-axis labels in Figure 7B and Figure 7D were listed as ‘contr.’ and ‘T’, respectively. However, the correct x-axis labels should be ‘contr.’ and ‘CP’, as these two graphs display data from CP-724714-treated cells (CP) and not from Tucatinib-treated cells (T). The corrected Figure 7 and its caption appear below.

Figure 7

In the published article, there was an error. The CD151-specific antibody used for the WB was not described correctly. A correction has been made to Section 2 Materials and methods, Sub-section Antibodies, inhibitors, and plasmids, Paragraph 1. This sentence previously stated: ‘A rabbit pAb raised against CD151 (ab185684) used for STED experiments was purchased from (Abcam, Amsterdam, Netherlands) and CD151-specific mouse mAb antibody (11G5a) for WB from Bio-Rad (Munich, Germany).’ The corrected sentence appears below:

‘A rabbit pAb raised against CD151 (ab185684) used for STED experiments was purchased from Abcam (Amsterdam, Netherlands) and a rabbit anti-CD151 serum generated against the recombinant large extracellular loop of CD151 (rCD151) used for WB after non-reducing SDS-PAGE was a kind gift from Fedor Berditchevski (University of Birmingham, United Kingdom).’

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

human papillomavirus, HPV16, promoter activity, ErbB2, HER2/neu, tyrosine kinase inhibitor, tucatinib, E6 E7 oncogene expression

Citation

Mikuličić S, Shamun M, Massenberg A, Franke A-L, Freitag K, Döring T, Strunk J, Tenzer S, Lang T and Florin L (2024) Corrigendum: ErbB2/HER2 receptor tyrosine kinase regulates human papillomavirus promoter activity. Front. Immunol. 15:1385729. doi: 10.3389/fimmu.2024.1385729

Received

13 February 2024

Accepted

19 February 2024

Published

29 February 2024

Volume

15 - 2024

Edited and reviewed by

Mirko Trilling, University of Duisburg-Essen, Germany

Updates

Copyright

*Correspondence: Luise Florin,

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics